Membrane vesicle preparation for eliminating intracellular staphylococcus aureus infection as well as preparation method and application of membrane vesicle preparation

By loading vancomycin into the membrane vesicles of Staphylococcus aureus and using ultrasound treatment, the problem of low delivery efficiency of vancomycin is solved, and efficient removal of MRSA infection in macrophages is achieved, which is of great therapeutic significance.

CN118949006APending Publication Date: 2024-11-15ARMY MEDICAL UNIV
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202410997679.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-24
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The prior art is difficult to effectively deliver vancomycin into macrophages, resulting in inefficiency in the treatment of methicillin-resistant Staphylococcus aureus (MRSA), and the side effects of vancomycin limit their high dose use.

Method used

By loading vancomycin into Staphylococcus aureus membrane vesicles and using sonication to improve its delivery efficiency, enabling it to enter macrophages efficiently while enhancing the antibacterial activity of macrophages.

Benefits of technology

It effectively reduces the amount of MRSA in macrophages, improves the efficiency of treating MRSA infection, and has high safety and biocompatibility.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118949006A_ABST
    Figure CN118949006A_ABST
Patent Text Reader

Abstract

The invention provides a membrane vesicle preparation for removing intracellular staphylococcus aureus infection and application of the membrane vesicle preparation, membrane vesicles of a staphylococcus aureus low-toxicity strain RN4220 are separated and purified, vancomycin is loaded by adopting an ultrasonic method, and the removal preparation is prepared, so that efficient delivery of vancomycin into macrophages is realized; the methicillin-resistant staphylococcus aureus in the macrophages can be effectively removed. By adopting the preparation provided by the invention, vancomycin can be effectively loaded into staphylococcus aureus membrane vesicles, the number of methicillin-resistant staphylococcus aureus infection in mouse peritoneal macrophages is remarkably reduced, and the preparation has relatively good biocompatibility and safety.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and in particular to a membrane vesicle preparation for clearing intracellular Staphylococcus aureus infection and an application thereof. Background Art

[0002] Bacterial infections have always been a threat to human health (Patini R, et al., Antibiotics (Basel) 2020; 9: 22.). In recent decades, antibiotics have remained an effective drug for treating bacterial infections. However, the abuse of antibiotics has led to the emergence of more and more drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA) (Lee AS, et al., Nat Rev Dis Primers 2018; 4: 18033). MRSA is a multidrug-resistant pathogen that can destroy the defense system of macrophages and survive and reproduce in macrophages during the infection process (Turner NA, et al., Nat Rev Microbiol 2019; 17: 203-218), leading to persistent and recurrent infections (Surewaard BG, et al., J Exp Med 2016; 213: 1141-1151). Vancomycin is the "last line of defense" for the clinical treatment of severe MRSA infections, but due to the low efficiency of vancomycin entering macrophages, it is impossible to reach an effective bactericidal concentration in the cell; at the same time, side effects such as nephrotoxicity limit the use of large doses of vancomycin to a certain extent (Jorch SK, et al., J Clin Invest 2019; 129: 4643-4656). Therefore, how to efficiently deliver vancomycin to macrophages so that the intracellular vancomycin reaches a concentration that effectively kills MRSA is the key to achieving the treatment of intracellular MRSA infection (Xie S, et al., J Control Release 2014; 187: 101-117).

[0003] In recent years, the development of nano drug carriers as intracellular drug delivery systems has become a hot topic. In pharmacy, the size of nanoparticle drug carriers is usually defined as 1nm to 1000nm (Younis MA, et al., Adv Drug Deliv Rev 2022; 181: 114083). The use of nano drug carriers is considered to be a potential measure to improve the transmembrane permeability of drugs, enhance intracellular drug accumulation, and increase the antibacterial activity of antibacterial drugs against drug-resistant strains (Zhou K, et al., Int J Nanomedicine 2018; 13: 7333-7347). Nanoparticles such as liposomes (Jorch SK, et al., J Clin Invest 2019; 129: 4643-4656), organic nanoparticles (Gao F, et al., ACS Infect Dis 2019; 5: 218-227), exosomes (Yang X, et al., J Control Release 2021; 329: 454-467) and inorganic nanoparticles (Xie B, et al., J Control Release 2023; 357: 371-378) are all nano drug delivery carriers that have attracted much attention. However, there are problems such as low delivery efficiency and overly complicated preparation processes to varying degrees, which greatly limits the application of the products. In recent years, researchers have proposed that membrane vesicles (MVs) secreted by bacteria are a potential drug delivery carrier, which can enter cells through protein mediation or phagocytosis (Jahromi LP, et al., AdvDrug Deliv Rev 2021; 173: 125-140). And its multi-antigenicity can trigger an immune response against the parent bacteria, involving innate and adaptive immune mechanisms in the host (Bitto NJ, et al., J Extracell Vesicles 2021; 10: e12080). Among them, researchers have reported that membrane vesicles secreted by Staphylococcus aureus can be efficiently phagocytosed by macrophages (Wang X, et al., Proc Natl Acad Sci USA 2020; 117: 3174-3184). Therefore, the development of Staphylococcus aureus membrane vesicles as nanodrug delivery carriers to improve the efficiency of vancomycin entering macrophages and improve the antibacterial activity of macrophages is a problem of concern in the present invention. Summary of the invention

[0004] In order to overcome the deficiencies of the above-mentioned prior art, the present invention provides a membrane vesicle preparation for clearing intracellular Staphylococcus aureus infection, wherein the method loads vancomycin into Staphylococcus aureus membrane vesicles by ultrasound, so that while efficiently delivering vancomycin into macrophages, the membrane vesicles can also improve the antibacterial activity of macrophages, thereby effectively clearing MRSA infection in macrophages under the synergistic effect of the two. The present invention has been verified by experiments that the vancomycin-loaded Staphylococcus aureus membrane vesicles obtained by the method of the present invention can effectively reduce the number of MRSA in infected mouse macrophages, have high safety and biocompatibility, and have important practical significance for the application in treating MRSA intracellular infection.

[0005] A preparation for clearing intracellular Staphylococcus aureus infection, comprising Staphylococcus aureus RN4220 membrane vesicles and vancomycin; wherein the mass ratio of Staphylococcus aureus RN4220 membrane vesicles to vancomycin is 1:0.2-1:3, and the vancomycin is encapsulated in the Staphylococcus aureus RN4220 membrane vesicles.

[0006] In one embodiment of the present invention, the membrane vesicles of Staphylococcus aureus RN4220 are obtained by separating and purifying Staphylococcus aureus RN4220 by ultrahigh-speed centrifugation; preferably, the specific conditions of the ultrahigh-speed centrifugation are centrifugation at 4°C and 200,000×g for 3 hours, and more preferably, the precipitate after centrifugation is resuspended in PBS and then the ultrahigh-speed centrifugation is repeated once.

[0007] In one embodiment of the present invention, the vancomycin is encapsulated in the membrane vesicles of Staphylococcus aureus RN4220 by a method comprising the following steps:

[0008] Staphylococcus aureus RN4220 membrane vesicles and vancomycin are mixed at a mass ratio of 1:0.2 to 1:3, subjected to probe ultrasonic treatment, and incubated statically after treatment. Then, unloaded vancomycin is removed, and finally the centrifugal column is eluted with sterile PBS to obtain a membrane vesicle preparation loaded with vancomycin; preferably, the processing parameters of the probe ultrasonic treatment are 30% power, 4s on / 2s off, 5 cycles, and incubated statically at 37°C for 1h after treatment.

[0009] In one embodiment according to the present invention, the removal of excess unloaded vancomycin is achieved by centrifuging through an ultrafiltration centrifuge tube (100 kDa).

[0010] The present invention also provides a method for preparing a preparation for eliminating intracellular Staphylococcus aureus infection, comprising:

[0011] 1) Separating and purifying the membrane vesicles of Staphylococcus aureus RN4220 by ultra-high speed centrifugation;

[0012] 2) The membrane vesicles of Staphylococcus aureus RN4220 and vancomycin are mixed in a mass ratio of 1:0.2 to 1:3, subjected to probe ultrasonic treatment, and then incubated; preferably, the processing parameters of the probe ultrasonic treatment are 30% power, 4s on / 2s off, and 5 cycles; more preferably, the static incubation condition is static incubation at 37° C. for 1 hour; preferably, the mass ratio of the membrane vesicles of Staphylococcus aureus RN4220 and vancomycin is 1:2;

[0013] 3) Use ultrafiltration centrifuge tubes (100 kDa) to remove excess unloaded vancomycin by centrifugation.

[0014] In one embodiment according to the present invention, the process further comprises step 4) washing the centrifugal column with sterile PBS to obtain the membrane vesicle preparation loaded with vancomycin, filtering the preparation with a 1 mL sterile syringe through a 0.22 μm filter head, and then packaging and storing the preparation.

[0015] In one embodiment of the present invention, the specific conditions of the ultra-high speed centrifugation are: 4°C, 200,000×g centrifugation for 3 h. Preferably, the precipitate obtained by centrifugation is resuspended in PBS and then ultra-high speed centrifugation is repeated once.

[0016] In one embodiment of the present invention, the centrifugation conditions in step 3) are 4°C, 4,000×g for 20 min.

[0017] The present invention further provides a pharmaceutical composition for treating Staphylococcus aureus infection, comprising the above-mentioned preparation or the preparation prepared according to the above-mentioned method, and pharmaceutically acceptable excipients.

[0018] The present invention also discloses use of the above-mentioned preparation or the preparation prepared according to the above-mentioned method, or the pharmaceutical composition in preparing a medicine for treating Staphylococcus aureus infection.

[0019] The beneficial effects of the present invention are:

[0020] 1) The membrane vesicle preparation for eliminating intracellular Staphylococcus aureus infection described in the present invention can effectively deliver vancomycin into macrophages by ultrasonically loading vancomycin onto Staphylococcus aureus membrane vesicles.

[0021] 2) The vancomycin-loaded Staphylococcus aureus membrane vesicles obtained by the method of the present invention can effectively improve the antibacterial activity of macrophages, and play a synergistic role with the bactericidal function of vancomycin.

[0022] 3) The vancomycin-loaded Staphylococcus aureus membrane vesicles obtained by the method of the present invention have high safety and biocompatibility.

[0023] Experiments have shown that the membrane vesicle preparation for clearing intracellular Staphylococcus aureus infection provided by the present invention can efficiently deliver vancomycin into macrophages and improve the antibacterial activity of macrophages, thereby effectively clearing MRSA in macrophages, which has important practical significance for the treatment of MRSA intracellular infection. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 This is a graph showing the results of detecting the content of vancomycin in MV-VAN preparation using high performance liquid chromatography.

[0025] Figure 2 The drug release curves of MV-VAN in the preparation or neutral PBS were detected by high performance liquid chromatography.

[0026] Figure 3 Transmission electron microscopy photographs of membrane vesicles MVs and MV-VAN preparations; the scale bar in the figure is 200 nm.

[0027] Figure 4 It is a characterization spectrum of membrane vesicles MVs and MV-VAN preparations; among them,

[0028] a is the particle size distribution of Staphylococcus aureus MVs and MV-VAN detected by nanoparticle size analyzer; b is the PdI value of MVs and MV-VAN detected by nanoparticle size analyzer; c is the membrane surface potential of MVs and MV-VAN detected by nanoparticle size analyzer. Data are expressed as mean ± standard deviation (SD) (n = 3), ** indicates p < 0.01, *** indicates p < 0.001.

[0029] Figure 5 The results of the test of the killing activity of MV-VAN preparation against MRSA in vitro by co-incubating with cultured MRSA in different treatment groups and then taking samples at different time points for plate culture and colony counting;

[0030] Figure 6Figure 1 is the efficiency diagram of membrane vesicle MVs and MV-VAN preparations entering macrophages with liposomes; a is the imaging observation of the efficiency of liposomes and Staphylococcus aureus MVs entering macrophages; b is the comparison of the fluorescence intensity of liposomes and Staphylococcus aureus MVs entering macrophages, where the arithmetic mean fluorescence values ​​of 149 cells in the liposome group and the arithmetic mean fluorescence values ​​of 142 cells in the MVs group. c is the imaging observation of the efficiency of free vancomycin and MV-VAN entering macrophages; d is the comparison of the fluorescence intensity of free vancomycin and MV-VAN entering macrophages, where the arithmetic mean fluorescence values ​​of 173 cells in the free vancomycin group and the arithmetic mean fluorescence values ​​of 190 cells in the MV-VAN group. Data are expressed as mean ± standard deviation (SD), ** indicates p < 0.01, *** indicates p < 0.001.

[0031] Figure 7 The figure shows the results of different treatment groups killing MRSA in macrophages;

[0032] Plate counts of intracellular MRSA were performed in different treatment groups after 12 and 24 hours of treatment in the macrophage intracellular MRSA infection model. Data are presented as mean ± standard deviation (SD) (n = 3), * indicates p < 0.05, ** indicates p < 0.01, and *** indicates p < 0.001.

[0033] Figure 8 The figure shows the killing effect of different treatment groups on MRSA in mouse macrophages; among them, the plate counts of MRSA in peritoneal macrophages were performed after the different treatment groups treated the intraperitoneal infection model of mice (n=4 per group). The data are expressed as mean ± standard deviation (SD), ** indicates p<0.01, and *** indicates p<0.001.

[0034] Fig. 9 The figure is a preliminary safety evaluation chart of membrane vesicle MV-VAN preparation; among them, a is the addition of different concentrations of Staphylococcus aureus MVs to macrophage culture medium, and the cell viability is evaluated at different time points; b is the tissue sectioning and HE staining of internal organs (heart, liver, spleen, lung, kidney) of mice after injection of different treatment group reagents to observe pathological changes; c is the detection of IL-6 content in mouse blood 6 hours after injection of different treatment group reagents; d is the detection of TNF-α content in mouse blood 6 hours after injection of different treatment group solvents. Data are expressed as mean ± standard deviation (SD) (n = 3; ns means p> 0.05). DETAILED DESCRIPTION

[0035] In order to make the technical problems, technical solutions and advantages to be solved by the present invention clearer, the following will be described in detail with reference to the accompanying drawings and specific embodiments. These embodiments are provided to enable a more thorough understanding of the present application and to fully convey the scope of the present application to those skilled in the art.

[0036] The words "include" or "comprising" mentioned throughout the specification and claims are open-ended terms and should be interpreted as "including but not limited to". The following description of the specification is a preferred embodiment of the present application, but the description is for the purpose of the general principles of the specification and is not intended to limit the scope of the present application. The scope of protection of the present application shall be determined by the attached claims.

[0037] The experimental methods used in the following examples are conventional methods unless otherwise specified. The materials, reagents, etc. used in the following examples are all commercially available unless otherwise specified.

[0038] Reagents, materials and equipment required for the experiment:

[0039] 1. Staphylococcus aureus RN4220 (purchased from Shanghai Qincheng Biotechnology Co., Ltd.)

[0040] 2. Staphylococcus aureus USA300 (purchased from Beijing Biobo Biotechnology Co., Ltd.)

[0041] 3. Macrophage RAW364.7 (purchased from Laibaiha (Shanghai) Biotechnology Co., Ltd.)

[0042] 4. Brain Heart Infusion (BHI) (purchased from Oxoid, UK)

[0043] 5. TSB (Trypticase Soy Broth Medium) culture medium (purchased from Oxoid, UK)

[0044] 6. Vancomycin (VAN) (purchased from Sigma, USA)

[0045] 7. Coomassie Brilliant Blue R-250 (purchased from Shanghai Biotech, China)

[0046] 8.SYTO 9 staining solution (purchased from Xinyan Bomei, China)

[0047] 9. TritonX-100 (purchased from Sangon Biotechnology, China)

[0048] 10. Tween-20 (purchased from Sangon Biotechnology, China)

[0049] 11. DAPI stain ready to use (purchased from Dowobio, China)

[0050] 12.4% paraformaldehyde tissue fixative (purchased from Biosharp, China)

[0051] 13. DIO staining solution (purchased from Dalian Meilun Biotechnology, China)

[0052] 14. HBSS buffer (purchased from Servicebio, China)

[0053] 15.DMEM (purchased from Thermo Fisher Scientific, China)

[0054] 16. Premium fetal bovine serum (purchased from Biosharp, China)

[0055] 17. Penicillin-streptomycin dual antibody (purchased from Thermo, USA)

[0056] 18.Cell Counting Kit (CCK kit) (purchased from ZETA LIFE, USA)

[0057] 19. FIYC-Vancomycin (purchased from Ruixibio, China)

[0058] 20. 0.22 μm sterilizing filter (purchased from Millipore, USA)

[0059] 21.0.45mm filter membrane (purchased from Shanghai Jizhi, China)

[0060] 22. Disposable sterile syringe 1mL (purchased from Liweining Company, China)

[0061] 23. Ultrafiltration centrifuge tube (MWCO = 100 kDa, purchased from GE Healthcare, UK)

[0062] 24. Dialysis bag (MW = 100K, purchased from Ruiswbio, USA)

[0063] 25. Cell culture flask-T25 (purchased from Servicebio, China)

[0064] 26. Mouse interleukin 6 (IL-6) kit (purchased from MEIMIAN, China)

[0065] 27. Mouse tumor necrosis factor α (TNF-α) kit (purchased from MEIMIAN, China)

[0066] 28.UP-50H ultrasonic crusher (purchased from Hielscher, Germany)

[0067] 29. Desktop centrifuge (purchased from Thermo, USA)

[0068] 30.Turning shaker (purchased from Shanghai Zhicheng, China)

[0069] 31. Constant temperature incubator (purchased from Shanghai Zhicheng, China)

[0070] 32.Himac ultra-high speed refrigerated centrifuge (purchased from HITACHI, Japan)

[0071] 33. Nanoparticle size analyzer (zatasizeNanoZSP, purchased from Malvern, USA)

[0072] 34. Ultra-high resolution laser confocal microscope (purchased from LSM 880, Germany)

[0073] 35. High performance liquid chromatography (HPLC, purchased from Agilent, Canada)

[0074] Preparation and storage method of the solution required for the experiment:

[0075] BHI liquid (solid) medium: Weigh 3.7 g of BHI dry powder, add it to 100 mL of ddH2O (solid, add 1.5 g of agar powder), mix well, sterilize with high pressure steam at 121°C for 20 minutes, and store at 4°C.

[0076] PBS buffer: Dissolve one packet of PBS powder in 1L ddH2O, mix thoroughly, sterilize at 121℃ high pressure steam for 20 minutes, cool naturally at room temperature, and store at 4℃.

[0077] DMEM cell culture medium: Add 10% high-grade fetal bovine serum and 1% penicillin-streptomycin double antibody to the purchased DMEM cell culture medium and store at 4°C;

[0078] 0.1% TritonX-100 HBSS buffer: Measure 10 mL of Hanks buffer, add 10 μL of TritonX-100 solution, mix well, and store at 4°C;

[0079] 0.05% Tween-20 PBS solution: Dissolve 1 pack of PBS powder in 1L ddH2O, add 500μL Tween-20 solution, stir evenly, and store at 4℃

[0080] Example 1 Preparation of Staphylococcus aureus MVs

[0081] Staphylococcus aureus is an opportunistic pathogen, and the virulence of different strains varies greatly. The virulence regulatory system of Staphylococcus aureus RN4220 has a gene mutation, which leads to low virulence of the strain, making it an ideal strain for preparing membrane vesicles MVs (Traber K & Novick R. Mol Microbiol 2006; 59: 1519-1530; Adhikari RP, et al. Infect Immun 2007; 75: 4534-4540). The steps for preparing MVs using RN4220 are as follows:

[0082] 1. Strain recovery

[0083] After the Staphylococcus aureus strain RN4220 was revived, it was inoculated on a BHI solid plate using the three-line method and cultured in a 37°C incubator overnight. The next day, a single colony of the RN4220 strain was picked and inoculated into 20 mL of BHI medium and cultured overnight at 37°C, 200 r / min, with shaking.

[0084] 2. Crude extraction of membrane vesicles

[0085] The overnight culture was transferred to 200 mL BHI liquid medium at a ratio of 1:100 and cultured at 37°C, 200 r / min, with shaking for 12 hours. After the culture was completed, centrifuged at 6,000×g, 4°C for 10 minutes, and the supernatant was taken and centrifuged at 10,000×g, 4°C for 10 minutes. The supernatant was filtered with a 0.45μm filter membrane to remove bacteria and bacterial fragments. The filtrate was concentrated using an ultrafiltration centrifuge tube with a molecular weight cutoff of 100kDa (MWCO=100kDa, purchased from GE Healthcare, UK). The concentrate was then ultracentrifuged at 200,000×g, 4°C for 3 hours, and the precipitate was dissolved with sterile PBS to obtain the crude extracted Staphylococcus aureus MVs.

[0086] 3. Purification of membrane vesicles

[0087] The crudely extracted Staphylococcus aureus MVs were washed twice with PBS, each time by ultracentrifugation at 200,000×g, 4°C for 3 h. The precipitate at the bottom was resuspended with sterile PBS, filtered with a 0.22 μm filter, diluted with sterile PBS to an appropriate concentration, and stored in a -80°C refrigerator after aliquoting.

[0088] Example 2: Preparation of Staphylococcus aureus MVs loaded with vancomycin

[0089] Staphylococcus aureus MVs were used as a drug delivery carrier to encapsulate vancomycin and prepare membrane vesicle preparations. The preparation method is as follows:

[0090] 1. Quantitative Detection of Staphylococcus aureus MVs

[0091] The amount of protein carried by membrane vesicles was detected by the Coomassie Brilliant Blue method, and the membrane vesicle protein was quantified using bovine serum albumin (purchased from Shanghai Biyuntian Biotechnology Co., Ltd.) as a reference.

[0092] 2. Vancomycin Loading

[0093] 100 μg, 90 μg, 80 μg, 60 μg, 40 μg, 30 μg of bacterial MVs were mixed with 20 μg, 30 μg, 40 μg, 60 μg, 80 μg, 90 μg of vancomycin in EP tubes, and the mixing ratios were 5:1, 3:1, 2:1, 1:1, 1:2 and 1:3, respectively. The samples were placed in a UP-50H ultrasonic disruptor (Hielscher, Germany) for probe sonication: 30% power, 4s on / 2s off, 5 cycles, and incubated at 37°C for 1 h.

[0094] 3. Purification of Encapsulated Preparations

[0095] The excess unloaded vancomycin was removed by centrifugation using an ultrafiltration centrifuge tube (MWCO = 100 kDa, GE Healthcare, UK), and the centrifugation conditions were: 4,000 × g, 4°C ultra-high speed centrifugation for 20 min. After washing the centrifuge column with sterile PBS to obtain the attenuated membrane vesicles loaded with vancomycin, a 1 mL sterile syringe was used to filter with a 0.22 μm filter head (Millipore, USA) to obtain the encapsulated preparation MV-VAN, and the optimal mixing ratio was selected by encapsulation efficiency detection.

[0096] Example 3: Determination of the efficiency of vancomycin encapsulation in Staphylococcus aureus MVs

[0097] The bactericidal efficacy of Staphylococcus aureus MVs preparation is proportional to the amount of vancomycin it encapsulates. The vancomycin encapsulation rate in membrane vesicle preparations prepared with different mixing ratios was detected by high performance liquid chromatography (HPLC) to select the optimal mixing ratio for preparation of the preparation.

[0098] 1. Preparation of standard curve

[0099] Vancomycin standard (purchased from Sigma, USA) was used to prepare solutions with concentrations of 50 μg / mL, 25 μg / mL, 12.5 μg / mL, 6.25 μg / mL, and 3.125 μg / mL. An equal volume of acetonitrile was added to the above solutions, vortexed and mixed, centrifuged at 18,000×g, 4°C for 20 min, and the supernatant was subjected to high performance liquid chromatography (HPLC, Agilent 1260, Agilent Technologies, Palo Alto, Canada) for detection. HPLC parameter configuration: C18 column (TC, 250×4.6 mm, 5 μm), flow rate: 1 mL / min, wavelength detection: 236 nm, column temperature 30°C, mobile phase: acetonitrile: potassium dihydrogen phosphate (pH: 3.2, concentration 0.05 mol / L) = 9.5:90.5, peak time: 9-10 min. The peak areas of different samples were measured respectively, and standard curves of different vancomycin concentrations were drawn.

[0100] 2. Determination of Vancomycin in Membrane Vesicle Preparations

[0101] Take 100 μL of each MV-VAN solution mixed in different proportions in Example 2, add an equal volume of acetonitrile, vortex mix, and ultrasonicate (30% power, 2 min), then transfer to a centrifuge tube, 18,000×g, 4°C, 20 min. Take the supernatant for HPLC detection, and calculate the area of ​​each sample peak ( Figure 1 ). Using the standard curve, the mass of vancomycin in each preparation was determined.

[0102] 3. Calculation of drug loading rate of membrane vesicles

[0103] The drug loading rate can be obtained by dividing the detected vancomycin mass by the mass of the membrane vesicles. The higher the drug loading rate, the better the loading effect. The best effect was found when the mass ratio of Staphylococcus aureus MVs to vancomycin was 1:2, and the drug loading rate was 25%±3.5%.

[0104] Example 4: Determination of release rate of membrane vesicle preparations

[0105] Drugs encapsulated in nanocarriers usually have a sustained-release function, so the dialysis bag combined with HPLC method was used to determine the drug sustained-release efficiency of the preparation of vancomycin encapsulated in Staphylococcus aureus MVs. The specific method is as follows:

[0106] 1. Sample Preparation

[0107] 460 μg of Staphylococcus aureus MVs and 920 μg of vancomycin (mass ratio 1:2) were ultrasonically mixed for drug loading, and three samples were set up for replication; the drug-loaded membrane vesicles were removed from the excess free vancomycin using an ultrafiltration centrifuge tube, and then eluted with sterile PBS, and finally each membrane vesicle preparation solution was 2.5 mL. Three other MVs of the same mass were taken, without vancomycin loading, as controls.

[0108] 2. Dialysis treatment

[0109] The eluted membrane vesicles loaded with vancomycin were added to an activated dialysis bag (MW cutoff = 100K, the released vancomycin can be transmitted to the waste liquid, purchased from Ruiswbio, USA), both ends were sealed, and the dialysis bag was placed in 17.5 mL PBS with a pH of 7.4 and incubated in a shaker at 37°C and 150 rpm. 1 mL of samples were taken at 0, 1, 2, 3, 4, 5, 6, 8, 12, 24 and 32 h, and 1 mL of PBS was added for replenishment after each sampling.

[0110] 3. Determination of Vancomycin Concentration

[0111] The sample was tested for vancomycin by HPLC, the peak area of ​​the sample was calculated, and the concentration of residual vancomycin in the membrane vesicle preparation at different time points was obtained from the standard curve. Finally, the release curve of the vancomycin-loaded membrane vesicle was prepared. The formula for calculating the release rate is as follows:

[0112]

[0113] Ct is the concentration of vancomycin at a certain moment. The results showed that the MV-VAN membrane vesicle preparation released the loaded vancomycin over time, and the release rate reached 80% at 8 hours ( Figure 2 ).

[0114] Example 5: Characterization of S. aureus MVs and MV-VAN preparations

[0115] As a new preparation, the characteristics of MVs and MV-VAN were further clarified through morphological observation and particle size analysis.

[0116] 1. Electron microscopic observation of Staphylococcus aureus MVs and their preparation MV-VAN

[0117] 50 μL of purified bacterial MVs or their preparation MV-VAN were dropped onto a copper grid, allowed to settle for 15 min, and then negatively stained with 2% phosphotungstic acid for 15 s. After the copper grid was dried for at least 1 hour, the morphological characteristics of bacterial membrane vesicles were observed using a transmission electron microscope (TEM; HT7700, Hitachi, Japan). Figure 3As shown, MVs and MV-VAN were mainly spherical, indicating that the morphology of S. aureus MVs would not change significantly after loading with vancomycin.

[0118] 2. Dynamic Light Scattering Detection of Particle Size and Surface Potential of MVs and MV-VAN

[0119] At 25°C, 1 mL of PBS buffer was used to resuspend the MVs or MV-VAN preparation of Staphylococcus aureus to be tested, and the particle size was detected and analyzed using a Malvern particle size detector (zatasizeNanoZSP, Malvern, USA). The membrane bubble resuspension was added to the sample pool of the detector, and the particle size, PdI and membrane surface potential of the bacterial membrane bubble were measured by dynamic light scattering. The results are shown in Figure 4 As shown, after the Staphylococcus aureus membrane vesicles were loaded with vancomycin, the average particle size increased, the particle uniformity improved, and the absolute value of the membrane surface potential increased.

[0120] Example 6: Evaluation of in vitro bactericidal activity of membrane vesicle MV-VAN preparation

[0121] MRSA strain USA300 is a highly toxic and highly drug-resistant strain prevalent worldwide, and its isolation rate has been increasing in recent years (Passalacqua KD, et al., Antimicrob Agents Chemother 2012; 56: 5212-5223). The bactericidal activity of membrane vesicle MV-VAN preparation against USA300 was investigated.

[0122] 1. Determination of MIC value of membrane vesicle MV-VAN against MRSA

[0123] To revive the bacteria, a single colony of the USA300 strain was picked and placed in 1 mL of BHI liquid medium. The culture was shaken at 37°C and 200 rpm / min for 6 h. The bacterial solution was diluted to 10 using a turbidity comparator. 8 CFU / mL, and then diluted to 10 using BHI liquid medium. 6 CFU / mL for later use. Take the membrane vesicle MV-VAN preparation and dilute it to 100μg / mL, 50μg / mL, 25μg / mL, 12.5μg / mL and 6.25μg / mL with PBS. Add 100μL of 10 6CFU / mL of bacterial solution, add 100μL of MV-VAN preparations of each concentration gradient to each empty space, and mix to form final concentrations of 50μg / mL, 25μg / mL, 12.5μg / mL, 6.25μg / mL and 3.125μg / mL. Observe after static culture in a 37℃ incubator for 18h. The results show that the MIC value of MV-VAN against USA300 is 12.5μg / mL.

[0124] 2. Bactericidal activity of MV-VAN against MRSA in vitro

[0125] Pick a single colony of USA300 strain and culture it in 1 mL BHI medium at 37°C, 200 rpm / min for 6 h. Dilute USA300 to 10 6 The experiment was divided into 5 groups, each with 3 parallel controls: Group 1: 100 μL PBS + 100 μL USA300 solution; Group 2: 100 μL vancomycin (VAN, concentration of 20 μg / mL) + 100 μL USA300 solution; Group 3: 100 μL MVs (concentration of 100 μg / mL) + 100 μL USA300 solution; Group 4: 100 μL MV+VAN (MVs concentration of 100 μg / mL, VAN concentration of 50 μg / mL) + 100 μL USA300 solution; Group 5: 100 μL MV-VAN (MVs concentration of 100 μg / mL) + 100 μL USA300 solution. Mix well in a 96-well plate, take 10 μL of culture solution at the following times: 0h, 2h, 6h, 12h and 24h, dilute with sterile PBS, dilute 100 times at 2h, 1,000 times at 2h and 6h, and 10,000 times at 12h and 24h, then take 50 μL of the dilution and spread it on TSB solid culture medium, count the colonies on each dilution plate at different time points. Results are shown in Figure 5 As shown, it was shown that MV-VAN could effectively release vancomycin and had good MRSA killing activity.

[0126] Example 7: Efficiency of MVs Uptake by Macrophages

[0127] To demonstrate the advantages of Staphylococcus aureus MVs as transmembrane drug delivery vehicles, the efficiency of liposomes and MVs taken up by macrophages was compared, and the efficiency of free vancomycin and MV-VAN entering macrophages was compared. It was confirmed that the membrane vesicle MV-VAN preparation can effectively deliver vancomycin into macrophages.

[0128] 1. Detection of the efficiency of liposomes and MVs entering macrophages

[0129] Macrophages RAW264.7 were seeded in confocal culture dishes (1×10 5 cells) and incubated overnight in a 37°C, 5% CO2 cell culture incubator. MVs and liposomes were incubated with 30μM DIO dye (Dalian Meilun Biotech, China) at 37°C for 90 minutes, and the lipid bilayer membrane could be stained green, and then the excess dye was removed. The pre-stained MVs and liposomes were added to the cells respectively and incubated for another 90 minutes in a 37°C, 5% CO2 cell culture incubator. The confocal culture dish was removed, the culture medium was discarded, and the cells were washed twice with PBS, and then 500μL 4% paraformaldehyde fixative was added and allowed to stand at room temperature for 15 minutes. The fixative was then discarded, and 200μL DAPI staining solution (Dowobio, China) was added, and allowed to stand at room temperature for 10 minutes. The cell nuclei were stained blue, and then the staining solution was removed. Rinse twice with 1mL PBS, each for 4 minutes. Finally, 300-500μL PBS was added to the confocal culture dish to prevent cell dehydration. The confocal dish was observed using a super-resolution laser scanning confocal microscope (LSM 880, Zeiss, Germany). The maximum excitation light of DIO dye was 484nm, and the maximum excitation light of DAPI dye was 358nm. Then the fluorescence intensity in macrophages was statistically analyzed. The results are shown in Figure 6 a, 6b, indicating that the efficiency of MVs engulfed by macrophages is significantly higher than that of liposomes.

[0130] 2. Detection of the efficiency of free vancomycin and MV-VAN preparation entering macrophages

[0131] FITC-modified vancomycin (FITC-VAN) emits green fluorescence under 484 nm excitation light. RAW264.7 cells were inoculated in confocal culture dishes (1×10 5 cells) and incubate overnight. Equal amounts of FITC-VAN and MV-FITC-VAN were incubated with the cells in a cell culture incubator at 37°C and 5% CO2 for 90 minutes. Remove the confocal culture dish, discard the culture medium, wash twice with PBS, then add 500μL 4% paraformaldehyde fixative, let stand at room temperature for 15 minutes, and then remove the fixative. Add 200μL DAPI staining solution, let stand at room temperature for 10 minutes to stain the cell nuclei blue, and then remove the staining solution. Rinse twice with 1mL PBS, 4 minutes each time. Finally, add 300-500μL PBS to the confocal culture dish to prevent cell dehydration. Use a super-resolution laser scanning confocal microscope to observe the confocal dish, and the maximum excitation light of the DAPI dye is 358nm. The fluorescence intensity in the macrophages was then statistically analyzed. The results are shown in Figure 6c, 6d, The results showed that MV-VAN significantly improved the efficiency of vancomycin phagocytosis by macrophages, proving the high efficiency of MVs as a transmembrane drug delivery carrier.

[0132] Example 8: Effect of MV-VAN in clearing MRSA in macrophages

[0133] An intracellular MRSA infection model of macrophage RAW264.7 was constructed in vitro to detect the effect of MV-VAN on the clearance of intracellular MRSA in macrophages and to verify whether there is a synergistic effect between MVs and VAN.

[0134] RAW264.7 cells were seeded in 24-well plates (1×10 5 / well), incubated in a 37°C, 5% CO2 incubator overnight. Then, MRSA was added to the cell culture medium of RAW264.7 macrophages at a ratio of 10-20 bacteria per cell (multiplicity of infection MOI = 10-20:1), and incubated in a cell culture incubator at 37°C, 5% CO2 for 2 hours. Lysostaphin was added at a final concentration of 20 μg / mL to kill extracellular bacteria, and new culture medium was replaced. Then PBS, VAN, MVs, MV+VAN, and MV-VAN were added to the cells, and the intracellular bacteria were diluted and counted on plates after incubation for 12 hours and 24 hours, respectively. The results are shown in Figure 7 As shown, it can be seen that the bactericidal effect of MV-VAN on MRSA in macrophages is significantly better than that of free vancomycin, and the effect of the combination of MVs and vancomycin is significantly better than that of vancomycin alone. This result shows that MVs and vancomycin have a synergistic effect in combating MRSA infection in macrophages.

[0135] Example 9: Effect of MV-VAN on MRSA clearance in macrophages in mice

[0136] Mice were housed at room temperature, and all animals had free access to food and water throughout the experiments. All animal experiments were approved by the Laboratory Animal Welfare and Ethics Committee of the Army Medical University, and animal handling procedures followed the guidelines established by the Animal Care Committee of the Army Medical University.

[0137] The experimental mice were 6-8 weeks old SPF female BALB / c mice. After three days of acclimatization, the mice were intraperitoneally inoculated with 5×10 7CFU of MRSA US300 strain were then randomly divided into 5 groups: PBS, vancomycin (VAN), MVs, MV+VAN mixed group and MV-VAN preparation group. VAN was selected as the positive control group because it is currently used as a standard treatment for invasive MRSA infections. After 24 hours, the mice were intraperitoneally injected with PBS, VAN (10 mg / kg), MVs (6 mg / kg), MV+VAN (equivalent to equal concentrations of MV and VAN) and MV-VAN (6 mg / kg). After 24 hours of treatment, 3 mL of sterile PBS was injected intraperitoneally into the mice for peritoneal lavage. 20 μg / mL lysostaphin was incubated with the lavaged peritoneal fluid at room temperature for 20 minutes to kill extracellular bacteria. Subsequently, the samples were washed 3 times with PBS to remove lysostaphin. The samples were incubated with HBSS (0.2% Triton-X) for 10 minutes to rupture the cells, and finally the bacteria were counted. The results are shown in Figure 8 , indicating that MV-VAN had the best effect on clearing MRSA in mouse macrophages, and the effect of the combination of MVs and vancomycin was significantly better than that of vancomycin alone, showing a synergistic effect, which was consistent with the results of in vitro cell experiments.

[0138] Example 10 Preliminary safety assessment of membrane vesicle MV-VAN preparation

[0139] The safety of MV-VAN preparations was preliminarily evaluated through cell experiments and mouse in vivo experiments, and effect controls were designed. The specific methods and results are as follows:

[0140] 1. Detection of the effect of membrane vesicle MV-VAN preparation on activation of macrophages

[0141] RAW264.7 macrophages were seeded in 96-well plates (2×10 3 Each well was incubated at 37°C and 5% CO2 for 24 hours. After replacing the culture medium, 10 μL of MV-VAN at different concentrations was added to each group of 3 replicate wells: 0 μg / mL, 25 μg / mL, 50 μg / mL, 100 μg / mL and 200 μg / mL. Then, it was placed in a 37°C and 5% CO2 incubator, and the cell activity was detected using CCK reagent (ZETA LIFE, USA) at different time points. The results are shown in Fig. 9 a, The results showed that different concentrations of MVs did not reduce the activity of macrophages, but increased the activity of macrophages at 24 hours.

[0142] 2. Observation of visceral organ damage in mice induced by membrane vesicle MV-VAN preparation

[0143] The mice were intraperitoneally injected with therapeutic doses of PBS, VAN, MVs, and MV-VAN. 24 hours later, the hearts, livers, spleens, lungs, and kidneys of the mice were removed and immersed in 4% paraformaldehyde. After fixation, the sections were sliced, stained with hematoxylin-eosin (HE), and histopathological examination was performed under a microscope. The results are shown in Fig. 9 b, HE staining results of tissue sections showed that compared with the PBS group, therapeutic doses of MVs and MV-VAN did not cause obvious pathological reactions in mice.

[0144] 3. Detection of the level of inflammatory factors produced by membrane vesicle MV-VAN preparation in mice

[0145] Mice were intraperitoneally injected with therapeutic doses of PBS, VAN, MVs, and MV-VAN. Six hours later, eye blood was collected and serum IL-6 and TNF-α levels were measured using ELISA. ELISA kits were purchased from MEIMIAN, China. The results are shown in Fig. 9 c and 9d, the results showed that compared with the PBS group, the therapeutic dose of MVs and MV-VAN did not cause obvious inflammatory response in mice.

[0146] The membrane vesicle MV-VAN preparation provided by the present invention has high safety in use.

[0147] The above is a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A membrane vesicle preparation for eliminating intracellular Staphylococcus aureus infection, characterized in that: The invention comprises membrane vesicles of Staphylococcus aureus RN4220 and vancomycin; wherein the mass ratio of the membrane vesicles of Staphylococcus aureus RN4220 to vancomycin is 1:0.2-1:3, and the vancomycin is contained in the membrane vesicles of Staphylococcus aureus RN4220.

2. The membrane vesicle preparation according to claim 1, characterized in that The membrane vesicles of Staphylococcus aureus RN4220 are obtained by separating and purifying Staphylococcus aureus RN4220 by ultrahigh-speed centrifugation; preferably, the specific conditions of the ultrahigh-speed centrifugation are centrifugation at 4°C and 200,000×g for 3 hours, and more preferably, the precipitate after centrifugation is resuspended in PBS and then ultrahigh-speed centrifugation is repeated once.

3. The membrane vesicle preparation according to claim 1 or 2, characterized in that The vancomycin is encapsulated in the membrane vesicles of Staphylococcus aureus RN4220 by a method comprising the following steps: Staphylococcus aureus RN4220 membrane vesicles and vancomycin are mixed at a mass ratio of 1:0.2 to 1:3, subjected to probe ultrasonic treatment, and incubated statically after treatment. Then, unloaded vancomycin is removed, and finally the centrifugal column is eluted with sterile PBS to obtain a membrane vesicle preparation loaded with vancomycin; preferably, the processing parameters of the probe ultrasonic treatment are 30% power, 4s on / 2s off, 5 cycles, and incubated statically at 37°C for 1h after treatment.

4. The membrane vesicle preparation according to claim 3, characterized in that The removal of excess unloaded vancomycin was achieved by centrifugation using ultrafiltration centrifuge tubes (100 kDa).

5. A method for preparing a membrane vesicle preparation for eliminating intracellular Staphylococcus aureus infection, characterized in that: include: 1) Separating and purifying the membrane vesicles of Staphylococcus aureus RN4220 by ultra-high speed centrifugation; 2) The membrane vesicles of Staphylococcus aureus RN4220 and vancomycin are mixed in a mass ratio of 1:0.2 to 1:3, subjected to probe ultrasonic treatment, and then incubated; preferably, the processing parameters of the probe ultrasonic treatment are 30% power, 4s on / 2s off, and 5 cycles; more preferably, the static incubation condition is static incubation at 37° C. for 1 hour; preferably, the mass ratio of the membrane vesicles of Staphylococcus aureus RN4220 and vancomycin is 1:2; 3) Use ultrafiltration centrifuge tubes (100 kDa) to remove excess unloaded vancomycin by centrifugation.

6. The method according to claim 5, characterized in that The method further comprises step 4) washing the centrifugal column with sterile PBS to obtain the membrane vesicle preparation loaded with vancomycin, filtering the preparation with a 1 mL sterile syringe through a 0.22 μm filter head, and then packaging and storing the preparation.

7. The method according to claim 5 or 6, characterized in that The specific conditions of the ultra-high speed centrifugation are: 4°C, 200,000×g for 3 hours. Preferably, the precipitate obtained by the centrifugation is resuspended in PBS and then ultra-high speed centrifugation is repeated once.

8. The method according to any one of claims 5 to 7, characterized in that The centrifugation conditions in step 3) are 4°C and 4,000×g for 20 min.

9. A pharmaceutical composition for treating Staphylococcus aureus infection, characterized in that: It comprises the membrane vesicle preparation according to any one of claims 1 to 4 or the membrane vesicle preparation prepared by the method according to any one of claims 5 to 8, and pharmaceutically acceptable excipients.

10. Use of the membrane vesicle preparation according to any one of claims 1 to 4, or the membrane vesicle preparation prepared according to the method according to any one of claims 5 to 8, or the pharmaceutical composition according to claim 9 in the preparation of a medicament for treating Staphylococcus aureus infection.

Citation Information

Cited By

  • Bionic nanometer delivery system based on MRSA outer vesicle coating and application thereof

    CN120114417A

  • Biomimetic nano-delivery system based on mrsa outer vesicle coating and applications thereof

    CN120114417B

  • Fusion membrane of staphylococcus epidermidis vesicles and turmeric-derived exosome-like vesicles as well as preparation method and application of fusion membrane

    CN120919253A